Amplia Therapeutics Limited
INNMF · OTC
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $2,377 | $1,407 | $2,004 |
| % Growth | -100% | 68.9% | -29.8% | – |
| Cost of Goods Sold | $24 | $140 | $71 | $331 |
| Gross Profit | -$24 | $2,237 | $1,336 | $1,674 |
| % Margin | – | 94.1% | 95% | 83.5% |
| R&D Expenses | $3,305 | $4,728 | $2,800 | $3,611 |
| G&A Expenses | $0 | $1,403 | $1,269 | $1,389 |
| SG&A Expenses | $1,303 | $1,415 | $1,336 | $1,429 |
| Sales & Mktg Exp. | $0 | $12 | $67 | $40 |
| Other Operating Expenses | $0 | -$149 | -$41 | -$23 |
| Operating Expenses | $4,608 | $5,994 | $4,095 | $5,016 |
| Operating Income | -$4,632 | -$3,757 | -$2,759 | -$3,342 |
| % Margin | – | -158.1% | -196.1% | -166.8% |
| Other Income/Exp. Net | $132 | -$1 | -$55 | -$2,021 |
| Pre-Tax Income | -$4,500 | -$3,758 | -$2,814 | -$5,364 |
| Tax Expense | -$1,739 | $0 | $0 | -$1,989 |
| Net Income | -$2,761 | -$3,758 | -$2,814 | -$3,374 |
| % Margin | – | -158.1% | -200% | -168.3% |
| EPS | -0.007 | -0.01 | -0.011 | -0.017 |
| % Growth | 37.5% | 6.3% | 36.2% | – |
| EPS Diluted | -0.007 | -0.01 | -0.011 | -0.017 |
| Weighted Avg Shares Out | 426,458 | 360,709 | 253,551 | 193,786 |
| Weighted Avg Shares Out Dil | 426,458 | 360,722 | 253,697 | 194,006 |
| Supplemental Information | – | – | – | – |
| Interest Income | $135 | $191 | $29 | $67 |
| Interest Expense | $3 | $0 | $0 | $32 |
| Depreciation & Amortization | $24 | -$33 | $43 | -$32 |
| EBITDA | -$4,473 | -$3,982 | -$2,800 | -$3,441 |
| % Margin | – | -167.5% | -199% | -171.7% |